Presentation: In this article we present our critical appraisal of a randomized clinical trial published in the New England Journal of Medicine in 2022. Study conclusions: The study compares four linezolid regimens (in addition to bedaquiline and pretomanid) for the management of drug-resistant tuberculosis. Finally, it shows that the regimen of 600 mg of linezolid for 26 weeks had less frequency of therapeutic failure and adverse events (compared to giving it for fewer weeks or at higher doses). Critical comment: The article is relevant because the appropriate dose of linezolid and duration of treatment with this agent to minimize adverse effects and maintain efficacy against highly resistant tuberculosis is still unclear. Despite some limitations such as low number of participants, high loss to follow-up, and no statistical comparisons between groups, the results are relatively reliabl...

Presentation: The NordICC study aimed to evaluate the long-term effects, with a 10-year follow-up, of inviting individuals aged 55 to 64 years to undergo a single colonoscopy screening for colorectal cancer (CC) compared to those who were not invited and did not undergo screening. Study findings: The group that received the colonoscopy screening invitation had lower risk of CC in comparison to the group that did not undergo screening. Critical commentary: The study's eligibility criteria closely resembled real-life scenarios. However, the inclusion of participants with CC risk factors and the potential differential effects in this subgroup remain unclear. The invitation for a single colonoscopy screening did not result in clinically important benefits in terms of CC risk, CC mortality, and all-cause mortality. On the other hand, complications associated with the screening procedure were ...